Is Sionna Therapeutics, Inc. Common Stock profitable?

Sionna Therapeutics, Inc. Common Stock is not currently profitable: it reported a net loss of $85.6M over the trailing twelve months.

What is Sionna Therapeutics, Inc. Common Stock's earnings per share?

Sionna Therapeutics, Inc. Common Stock's diluted EPS over the trailing twelve months is $-411.51.

Where does Sionna Therapeutics, Inc. Common Stock's income statement data come from?

Every line is extracted from Sionna Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Sionna Therapeutics, Inc. Common Stock SION Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Research and development	$65.56M+8.8%	$60.26M+1.5%	$59.35M-12.6%	$67.89M+11.8%	$60.74M+6.0%
General and administrative	$33.36M+16.2%	$28.72M+18.9%	$24.16M+22.0%	$19.8M+21.2%	$16.33M+23.1%
Other operating expenses	$98.92M+11.2%	$88.98M+6.6%	$83.5M-4.8%	$87.68M+13.8%	$77.07M+9.2%
Total operating expenses	$98.92M+11.2%	$88.98M+6.6%	$83.5M-4.8%	$87.68M+13.8%	$77.07M+9.2%
Operating income	-$98.92M-11.2%	-$88.98M-6.6%	-$83.5M+4.8%	-$87.68M-13.8%	-$77.07M-9.2%
Interest income	$13.12M-1.4%	$13.3M+8.6%	$12.24M+9.9%	$11.14M+11.0%	$10.04M+22.9%
Other income (expense), net	$13.36M-2.6%	$13.71M+6.9%	$12.83M+8.3%	$11.84M+10.2%	$10.75M+21.2%
Net income	-$85.57M-13.7%	-$75.27M-6.5%	-$70.68M+6.8%	-$75.84M-14.3%	-$66.32M-7.5%
Diluted earnings per share	-$411.510.0%	-$411.53+0.7%	-$414.26+1.2%	-$419.47+84.6%	-$2,719.47+58.5%
Basic earnings per share	-$411.510.0%	-$411.53+0.7%	-$414.26+1.2%	-$419.47+84.6%	-$2,719.47+58.5%
Weighted-average shares, diluted	129.2M+16.5%	110.9M+48.3%	74.8M+114%	35M+0.1%	34.9M+318%
Weighted-average shares, basic	129.2M+16.5%	110.9M+48.3%	74.8M+114%	35M+0.1%	34.9M+318%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$85.95M-14.5%	-$75.1M-5.7%	-$71.03M+5.9%	-$75.5M-14.4%	-$66.01M-7.7%
Other Nonoperating Income	$242K-42.2%	$419K-28.4%	$585K-16.9%	$704K-0.4%	$707K+1.3%
EBIT	-$98.92M-11.2%	-$88.98M-6.6%	-$83.5M+4.8%	-$87.68M-13.8%	-$77.07M-9.2%
EBITDA	-$98.42M-11.2%	-$88.47M-6.6%	-$82.98M+4.7%	-$87.06M-14.0%	-$76.34M-9.3%
EBITDA	-$98.42M-11.2%	-$88.47M-6.6%	-$82.98M+4.7%	-$87.06M-14.0%	-$76.34M-9.3%
EBIT	-$98.92M-11.2%	-$88.98M-6.6%	-$83.5M+4.8%	-$87.68M-13.8%	-$77.07M-9.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is Sionna Therapeutics, Inc. Common Stock profitable?: Sionna Therapeutics, Inc. Common Stock is not currently profitable: it reported a net loss of $85.6M over the trailing twelve months.
What is Sionna Therapeutics, Inc. Common Stock's earnings per share?: Sionna Therapeutics, Inc. Common Stock's diluted EPS over the trailing twelve months is $-411.51.
Where does Sionna Therapeutics, Inc. Common Stock's income statement data come from?: Every line is extracted from Sionna Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.